Immune trajectories in early life impacting HIV pathogenesis and viral control in perinatally infected children - despite antiretroviral therapy (art), children with perinatal HIV (PHIV) remain at…
Active Grant Awarded
- Award ID
- R01AI203548
- Recipient
-
Universita' Degli Studi DI Roma Tor Vergata UEI XPNML7MBWL86
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $444,437
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 4% complete
- Place of performance
- Italy
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Universita' Degli Studi DI Roma Tor Vergata (doing business as UNI Roma2) $444,437 on September 4, 2026, under Grant R01AI203548 in the Allergy and Infectious Diseases Research program (CFDA 93.855). The Ricerca Internazionale division is the recipient's named division. The recipient will perform the work in Italy. The ultimate completion date is August 31, 2031, and the $444,437 is the dollars obligated.
The grant funds a study of early immune development in children with perinatal HIV, examining how early immune events shape long-term viral control and susceptibility to co-infections. Aim 1 assesses how DNA methylation and chromatin accessibility influence HIV reservoir establishment in the first months of life, measured by cell-associated HIV DNA quantification. It covers children who started antiretroviral therapy early and were monitored during periods of poor adherence (EARTH) and during viral rebound in the context of analytical treatment interruption (PENTA11). Aim 2 defines HIV-specific NK, monocyte, and T cell responses present early in infection and longitudinally against viral load dynamics. It compares these responses with those elicited by early-life BCG/TB and CMV exposures and explores HIV reservoir composition within CMV-specific T cells.
Description
Immune trajectories in early life impacting HIV pathogenesis and viral control in perinatally infected children - despite antiretroviral therapy (art), children with perinatal HIV (PHIV) remain at risk for immune dysfunction, suboptimal vaccine responses, and CO-infections. PHIV occurs during a critical window of immune development, yet the early immune events that shape long-term virologic control and govern susceptibility to CO-infections remain largely undefined. This study seeks to define the early immune responses against HIV and to investigate how these are influenced by virologic control (through art-mediated suppression) and overall immune programming in PHIV. Our central hypothesis is that immune imprinting during periods of active viremia- particularly in the absence of art-has lasting effects on viral rebound dynamics and all pathogen-specific immunity later in life. This study leverages two distinct and rare, longitudinal cohorts of children with perinatal HIV with detailed clinical and virologic follow-up to address this question. Aim 1 will assess how epigenetic changes, including DNA methylation and chromatin accessibility influence HIV reservoir establishment in first few months of life (as measured by cell-associated HIV DNA quantification) in children who initiated art early and were subsequently monitored during periods of poor adherence (EARTH) and during viral rebound in the context of analytical treatment interruption (PENTA11). Aim 2 will define HIV-specific innate and adaptive responses-particularly NK, monocyte, and T cell function-present early during infection and longitudinally with relation to viral load dynamics and compare these to responses elicited by early-life exposures including BCG/TB and CMV. In this aim we will further explore the composition of HIV reservoir within CMV specific T cells, following the hypothesis that early immune dynamics shape permissiveness to reservoir and persistence hence providing targets for future cure strategies. Aim 3 will longitudinally profile plasma proteomic inflammatory signatures to identify early predictors of viral control and immune activation in children with PHIV and find associations with clinical events (COINFECTION/ILLNESSES). This project is innovative in its use of rare longitudinal pediatric cohorts experiencing art interruption or poor adherence, coupled with deep immunologic and multi-omic profiling. By focusing on NK cells and monocytes, the study will investigate potential evidence for trained immunity in PHIV- a concept previously shown with BCG vaccination. Using functional assays, proteomics, and single-cell multi- omic technologies, we will generate a comprehensive dataset across 60 participants with multiple longitudinal samples over childhood or after analytical treatment interruption. Findings will advance our understanding of immune programming in pediatric HIV and address gaps in knowledge related to overlapping infectious exposures in early life where opportunities for early immune intervention are most impactful. 1
Quick answers
Who received award R01AI203548?
R01AI203548 was awarded to Universita' Degli Studi DI Roma Tor Vergata by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 4, 2026.
How much is award R01AI203548 worth?
$444,437 has been obligated on R01AI203548.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award